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tarradrienn@freemail.huAbstractThe aim of the present study was to find out whether early cardiac changes in patients
receiving chemotherapy can be detected by the conventional and deformation parameters
of 2D and 3D echocardiography. Twenty-five healthy subjects with normal regional left
ventricular function (group 1) and 25 patients receiving chemotherapy (group 2) underwent
2D and 3D transthoracic echocardiography (Toshiba Artida Medical System). All patients
(group 2) were examined before and during cardiotoxic chemotherapy at a 3-month follow-
up. Left ventricular volumes, ejection fraction, muscle mass, global longitudinal, global
radial, global circumferential strain, and rotation were analyzed with 2D and 3D
echocardiography, while twist and time-to-peak-intervals were analyzed with 3D
echocardiography. For left ventricular volumes and muscle mass, no significant differences
were seen between the two study groups (P!0.05). According to our results, myocardial
dysfunction induced by cardiotoxic chemotherapy can be detected by 2D global radial strain.
Detecting myocardial dysfunction by global longitudinal and circumferential strain requires
more than 3 months follow-up. Changes in rotation, twist or time-to-peak intervals could
not be verified at the 3-month follow-up in the present study. 2D global radial strain seems
to be the most sensitive and robust parameter to detect early myocardial damage during
chemotherapy. 3D echocardiography is not yet an established method to detect myocardial
damage in clinical practice due to lower spatial and temporal resolution.Key Words
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Cardiotoxicity is the most important side effect of
anthracycline and other chemicals affecting the myo-
cardium. It is well known that anthracyclines and
trastuzumab induce left ventricular dysfunction. Two
types of cardiotoxicity are distinguished (1, 2). The early-
onset anthracycline-induced cardiotoxicity occurs within
the 1st year after chemotherapy. This type of cardio-
toxicity is difficult to treat and in most cases leads to theworsening of cardiac function. Thus, there is a consider-
able risk for developing late-onset anthracycline-induced
heart failure. Unfortunately, heart failure therapy can
hardly influence the natural course of this type of
myocardial damage. The other type of cardiotoxicity
causes a reversible deterioration of myocardial function
after cancer therapy. It is mostly observed in patients
treated with cyclophosphamide, and is mainly due to
edema and pericardial affections, and may be thewww.echorespract.com
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Age 45G12 63G15 0.37
Male 16 (64%) 11 (44%) 0.13
Female 9 (36%) 14 (56%) 0.13
Smoker 6 (24%) 7 (28%) 0.71
Alcohol consumption 0 (0%) 0 (0%) NS
Arterial hypertension 5 (20%) 11 (44%) 0.41
Coronary heart disease 0 (0%) 2 (8%) 0.15
Pulmonary embolism 0 (0%) 1 (4%) 0.31
Diabetes mellitus type 2 0 (0%) 5 (20%) 0.16
Peripheral arterial
disease
0 (0%) 2 (8%) 0.15
Hypercholesterinemia 0 (0%) 2 (8%) 0.15
Chronic obstructive
pulmonary disease
0 (0%) 4 (16%) 0.34
b-blocker therapy 10 (0%) 7 (28%) 0.29
Ace-inhibitor therapy 11 (0%) 5 (20%) 0.29
Calcium antagonist
therapy
0 (0%) 2 (8%) 0.15
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induced factors (3, 4).
For conventional analysis, left ventricular volumes
and left ventricular ejection fraction (LVEF) are the most
widely used parameters to detect cardiotoxicity, whereas
changes in ejection fraction seem to underestimate cardiac
damage (5, 6). Deformation analysis, especially modern
parameters such as rotation and twist, seems to be a
promising tool to detect myocardial affection at an earlier
stage; therefore, cancer therapy can be adjusted, and
irreversible early-onset anthracycline-induced myocardial
damage can be avoided.
The aim of the present study was to find out whether
early cardiac changes in patients receiving chemotherapy
can be detected by the conventional and deformation
parameters of 2D and 3D echocardiography. It was
hypothesised that global radial-, circumferential- and
longitudinal strain, rotation and twist are more sensitive
than LVEF at detecting early cardiac changes within 3
months of chemotherapy course.Methods
Study sample
From November 2012 to April 2013 two groups of 25 and
25 subjects respectively (nZ50) were enrolled in the study.
All subjects provided informed consent after full expla-
nation of the purpose and nature of the study. All
procedures were approved by the local ethical committee.
Subjects with LVEF !30% before chemotherapy, cardiac
arrhythmias, mild or severe valvular stenoses or regurgita-
tions, prosthetic valves, pacemaker and insufficient
image quality were excluded. Only subjects with excellent
image quality were included in the study. Excellent image
quality enables reliable tracking of themyocardial speckles
and, therefore, good tracking curves. In group 1 twenty-
five healthy subjects (controls) free from major cardiovas-
cular diseases or cardiovascular risk factors were analyzed.
In group 2 twenty-five patients with various types of
malignancy undergoing several types of cardiotoxic
chemotherapy were investigated before and during
chemotherapy at a mean follow-up of 3 months (G2
weeks). Clinical data of all controls (group 1) and all
patients (group 2) are shown in Table 1. The various tumor
types included in the study are acute myeloid leukaemia
(1), B-cell non-Hodgkin lymphoma (1), multiple myeloma
(2), breast (10), stomach (4), lung (2), hepatocellular
(1), thyroid (1) and lingual cancer (2) and renal cell
carcinoma (1).www.echorespract.comChemotherapy was performed with anthracycline
(nZ7), platinium-based antineoplastic agents (nZ4),
taxoids (nZ5), paclitaxel (nZ1), MABs (nZ6), kinase
inhibitors (nZ2), alkylating agents (nZ3) and their
combination (taxoid-anthracycline, MAB-anthracycline,
or MAB-platinum based antineoplastic agent).Ehocardiographic methods
All controls and patients underwent 2D and 3D transthor-
acic echocardiography according to the European and
American guidelines using Toshiba Artida Medical System
(Zoetermeer, The Netherlands) with PST-25SX 1 MHz to
4 MHz phased-arraymatrix probe for 3D image acquisition
(7, 8). LVEF, left ventricular end-diastolic volume
(LVEDV), left ventricular end-systolic volume (LVESV),
left ventricular musclemass and global longitudinal (GLS),
global radial (GRS) and global circumferential strain (GCS)
were measured offline using the 16-segment model of 2D
and 3D echocardiography.
2D parasternal short axis views were acquired at the
level of the left ventricular apex, the papillary muscles and
the mitral valve for determination of global radial and
circumferential strain by 2D speckle tracking (ST). 2D apical
long axis, two- and four-chamber views were acquired for
determination of global longitudinal strain by 2D ST. 2D
apical views were acquired at fixed sectional planes with
differences ofw608 between each other. All 2D views were
compared to views of the triplane approach. In addition,
rotationandtwistwere analyzedby3DST.Rotation refers to
myocardial rotational displacement around the long axis of82
Table 2 Comparison of conventional parameters between
groups 1 and 2 and between different time points (group 2








3D LVEF (%) 57G9 50G16*,a 49G7*,b
3D LVEDV (ml) 108G36 113G22 108G28
3D LVESV (ml) 47G25 56G14 55G16
3D muscle mass (g) 133G24 150G29 149G27
LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic
volume; LVESV, left ventricular end-systolic volume.
aComparison between groups 1 and 2 (before chemotherapy).
bComparison between groups 1 and 2 (during chemotherapy).
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left ventricular rotation is referred to as the net LV twist
angle (9). Peak strainwasmeasuredduring the ejection time
in patients with normal deformation patterns, and after
aortic valve closure in patients with post-systolic peak
strain. The time-to-peak interval describes the time interval
between aortic valve opening and the maximum strain
during systole. Longitudinal, radial and circumferential
time-to-peak intervals were measured in all 3D data sets
of all controls and patients. LVEF was measured with
semiautomatic 3D wall motion tracking (wall motion
tracking Software, Toshiba Medical Systems). According to
the methodological prerequisite for 2D ST, the frame rate
has to be between 40 and 80 frames/s. In the present data
sets, the frame rate was between 30 and 60 fps, with amean
value of 57G6 and 25G2 in 2D and 3D ST respectively.
The width of the tracking area was manually selected.Table 3 Comparison of deformation parameters between groups
during chemotherapy); *P value !0.05.
Group 1
3D global radial strain (%) 34G16.67
3D global circumferential strain (%) K28G1.71
3D global longitudinal strain (%) K14G1.52
2D global radial strain (%) 23G9.38
2D global circumferential strain (%) K23G3.77
2D global longitudinal strain (%) K16G2.90
2D rotation (8) 1.3G0.27
3D rotation (8) 3.5G0.28
3D twist (8/cm) 3.5G2.24
3D time-to-peak interval (radial) (ms) 402G79.09
3D time-to-peak interval (circumferential) (ms) 359G70.17
3D time-to-peak interval (longitudinal) (ms) 375G68.28
aComparison between groups 1 and 2 (before chemotherapy).
bComparison between groups 1 and 2 (during chemotherapy).
cComparison between group 2 before and group 2 during chemotherapy.
www.echorespract.comIn all controls and patients, full myocardial tracking was
performed. In patients with mild to moderate left ventri-
cular hypertrophy, tracking areas were adjusted to the
wall thickness to ensure full myocardial tracking. The end-
systole was determined automatically by the software at
the time of aortic valve closure.Statistical analysis
Mean values and S.D. were calculated. Comparisons
between groups 1 and 2 were performed by independent
sample t-test. In group 2, data obtained before and after
chemotherapy were compared with the help of paired
sample t-test. P values!0.05 were considered statistically
significant. Statistical analysis was carried out with SPSS
Software v. 17.0 (SPSS, Inc.).Results
In the present study, 16 segments of 25 controls and 25
patients were tracked and analyzed with 2D and 3D ST and
3D wall motion tracking. Conventional parameters are
shown in Table 2. Compared to group 1, LVEF was reduced
in group 2 at both time points (before and after
chemotherapy). However, LVEF was not different in
group 2 at the 3-month follow-up. For left ventricular
volumes and left ventricular muscle mass, no significant
differences were observed in the two study groups
(Table 2). In comparison to group 1, 2D GCS and 2D GLS
were significantly higher at the 3-month follow-up,



















2D parasternal short axis view at the level of the mitral valve (c) and the
corresponding radial strain curves (f) before chemotherapy are shown.
Below the corresponding view (i) and radial strain curves (l) during
chemotherapy after 3 months are shown. The peak radial strain at the
beginning of the chemotherapy is 39.4% and after 3 month is 42.1%.
Figure 2
2D parasternal short axis view at the level of the left ventricular apex
(a) and the corresponding circumferential strain curves (d) before
chemotherapy are shown. Below the corresponding view (g) and
circumferential strain curves (j) during chemotherapy after 3 months
are shown. The peak circumferential strain at the beginning of the
chemotherapy is K20.5%) and after 3 months is K18.5%.
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However, for 2D radial strain significant differences were
observed between group 1 and baseline group 2 data
(before chemotherapy), and between baseline and
3-month follow-up group 2 data (Table 3). 2D views and
the corresponding strain curves are shown in Figs 1, 2, 3, 4,
and 5. Values of 3D global circumferential strain were
significantly higher in group 2 (both before and during
chemotherapy) in comparison to group 1 (Table 3). In
contrast, no differences were observed in group 2 before
and during chemotherapy. 3D radial, circumferential and
longitudinal strain curves are shown in Fig. 6. A subgroup
analysis was additionally performed with 3D ST in patients
treated with anthracycline (nZ7). There was no difference
between baseline and 3-month follow-up values (global
radial strain 31.12G9.23 vs 29.85G18.46, globalwww.echorespract.comcircumferential strain 23.31G4.21 vs K22.87G4.10,
global longitudinal strain K12.56G2.45 vs K12.72G
2.91). For 3D rotation, 3D twist and 3D time-to-peak
intervals, no significant differences were seen (Table 3).Reproducibility
In ten randomly selected patients, 2D and 3D measure-
ments were performed by another investigator twice
within 5 weeks to determine intra-observer variability. In
addition, in ten randomly selected patients, 2D and 3D
measurements were carried out by two independent
investigators to determine inter-observer variability.
Intra-observer and inter-observer variability of strain
measurements were 4.1G1.9% and 6.1G1.8%,
respectively.84
Figure 3
2D apical long axis view (a) and the corresponding longitudinal strain
curves (d) before chemotherapy are shown. Below the corresponding view
(g) and longitudinal strain curves (j) during chemotherapy after 3 months
are shown. The peak longitudinal strain at the beginning of the
chemotherapy is K24.2% and after 3 months is K25.6%.
Figure 4
2D apical two-chamber view (b) and the corresponding longitudinal strain
curves (e) before chemotherapy are shown. Below the corresponding view
(h) and longitudinal strain curves (k) during chemotherapy after 3 months
are shown. The peak longitudinal strain at the beginning of the
chemotherapy is K20.6% and after 3 months is K20.5%.
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In clinical practice LVEF is the most commonly used
parameter to detect damages in the heart evoked by
chemotherapy. Recently, new parameters have been
established in deformation imaging for the evaluation of
LV function in clinical practice. With the help of this
method, follow-up investigations can be carried out
during chemotherapy. It is known that strain and LVEF
are different entities. Global strain reflects the fractional
change of LV dimensions, comparing the maximum end-
diastolic dimension with the maximum contracting state
at systole. In contrast, LVEF reflects the volumetric
fraction, which depends on the size and shape of the left
ventricle, the contraction of the global myocardium, the
integrity of the mitral and aortic valve, and diastolic
filling. In a cohort of patients with preserved myocardialwww.echorespract.comfunction and no or only mild valvular affections as well
as with a good acoustic window, global strain was shown
to be more robust than LVEF to characterize global
LV systolic function (10). Sawaya et al. (11) have shown
that the predictive value of LVEF to detect sequelae of
cardiotoxicity in early phase is very low in comparison to
strain and myocardial markers. In their study, a hetero-
geneous group of patients treated with chemo- and
radiotherapy was investigated, and it was found that
reduced longitudinal and radial strain obtained after
3 months of cancer treatment may predict later develop-
ment of cardiotoxicity. Stoodley et al. (12) have observed
reduced longitudinal and radial strain 1 week after
anthracycline therapy. In the present study the mean
strain values of 3D radial and 3D circumferential strain
were reduced in the patient cohort at baseline suggesting
that patients with already reduced myocardial function85
Figure 5
2D apical four-chamber view (c) and the corresponding longitudinal strain
curves (f) before chemotherapy are shown. Below the corresponding view
(i) and longitudinal strain curves (l) during chemotherapy after 3 months
are shown. The peak longitudinal strain at the beginning of the
chemotherapy is K17.7% and after 3 months is K24.5%.
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resolution of 3D speckle tracking, no significant changes
were detected within the first 3 months of cancer
treatment. In contrast, 2D radial strain was already
reduced 3 months after the beginning of chemotherapy,
which suggests that 2D radial strain seems to be an early
predictor for myocardial damage even in patients with
already reduced LVEF. A higher variability of radial strain
measurements was observed, which may be the conse-
quence of the different orientations of cardiac muscle
fibers. Most longitudinal muscle fibers are normally
located in the subendomyocardial layers, which are
mainly represented by longitudinal strain. Whereas
circumferential muscle fibers are oriented in the subepi-
myocardial layers, which are mainly represented by
circumferential strain (7, 13, 14). However, there are no
muscle fibers in the radial direction. Radial strain is thewww.echorespract.comsummation of both longitudinal and circumferential
muscle fibers. In addition, the higher variability of radial
strain compared to longitudinal strain (Table 3) may be
explained by methodological issues such as spatial
resolution.
ST analysis is based on specific gray scale patterns
that are detected frame by frame during the heart cycle.
Speckles arise due to reflexions, and they show a
correlation to morphology and tissue but are also
influenced by ultrasound wave interactions. Some of
these speckles may disappear due to tissue alteration
during therapy. In 2D and 3D ST, remarkable differences
were seen among controls (group 1) and patients (group 2).
There were significant differences of 2D and 3D radial
and 3D circumferential strain between controls (group 1)
and patients (group 2) before chemotherapy. This is
presumably due to the different spatial resolutions of the
two kinds of method. As the differences between 2D and
3D speckle tracking are not homogeneous for radial strain,
these observations may be explained by methodological
issues of resolution and different software algorithms.
Moreover, all strain values were quite low, which may be
due to different vendor-specific software algorithms and
smaller left ventricular cavities of the study subjects.
During the measurements of the circumferential
strain and radial strain, speckles move away from the 2D
short axis view as a result of the twisting cardiac motion.
This ‘out-of-plane motion’ means that speckles were not
tracked over the complete cardiac cycle. With the help of
3D echocardiography, these speckles are detected more
precisely during the complete cardiac cycle (14). Accord-
ing to our results, circumferential strain values were lower,
while radial strain values were higher with 3D ST,
compared to 2D ST (Table 3). This is presumably due to
the difference of vendor-specific spatial resolution and the
corresponding software algorithms. Variability was lower
and reproducibility was higher with 3D ST because the
apical sectional planes can be better standardized. Inap-
propriate shortening views can obviously be avoided by
simultaneously acquired standardized sectional planes.
However, 3D ST has more artefacts and different results
compared to 2D ST, even if the same frame rates are used.
Consequently, early myocardial changes of strain may not
be detected by 3D ST, as 3D ST is performed with a lower
spatial resolution and frame rate than 2D speckle tracking.
With the help of speckle tracking, early subclinical
changes are detectable. For modern parameters, e.g.
rotation and twist, no differences were seen. This may be
explained by the fact that these values are measured in the
circumferential direction similar to circumferential strain.86
Figure 6
3D radial strain curves of a patient before (a) and during (b) chemotherapy
after 3 months are shown. 3D circumferential strain curves of a patient
before (c) and during (d) chemotherapy after 3 months are shown.
3D longitudinal strain curves of a patient before (e) and during (f)
chemotherapy after 3 months are shown.
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3 months of anthracycline chemotherapy, an increase
in time-to-peak interval is observed. In contrast to their
findings, changes in 3D rotation, twist or time-to-peak
interval could not be detected after 3 months in the
present study.Conclusion
Myocardial dysfunction induced by cardiotoxic che-
motherapy can be detected by conventional and defor-
mation parameters using ST. 2D global radial strain seems
to be the most sensitive and robust parameter to detect
early myocardial damage during chemotherapy, already
after 3 months. For the detection of myocardial damage
by 2D global longitudinal and circumferential strain,
follow-ups after more than 3months seem to be necessary.
The detection of myocardial damage by 3D ST has not yet
been established for clinical practice due to lower spatial
and temporal resolution. Thus, our study results suggest
that in contrast to 2D ST, 3D ST seems to be limited to
detecting subclinical myocardial damage only in patients
receiving chemotherapy.Limitations
The major limitation of the present study is the small
number of study subjects. For this reason, further
subgroup analyses, e.g. the effect of the various chemo-
therapy drugs on LV function, may not show relevant
results. In addition, the representation of the chemo-
therapy drugs was inhomogeneous in the present study.
A further limitation is that only controls and patients
with excellent image quality were included. Thus, fullwww.echorespract.commyocardial tracking of all left ventricular segments could
be obtained only in these data sets. However, it can be
assumed thatmyocardial deformation occurred in subjects
with bad and excellent image quality.Declaration of interest
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